Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Johnson and Johnson
Medtronic
McKinsey
Mallinckrodt

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR AFATINIB DIMALEATE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Afatinib Dimaleate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02122172 ↗ Afatinib in Advanced Refractory Urothelial Cancer Recruiting National Cancer Institute (NCI) Phase 2 2013-10-30 This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die.
NCT02122172 ↗ Afatinib in Advanced Refractory Urothelial Cancer Recruiting University of Chicago Phase 2 2013-10-30 This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die.
NCT02131259 ↗ Long-term Observation PMS for Afatinib Completed Boehringer Ingelheim 2014-05-07 In Japan, post-approval execution of post marketing surveillance (PMS) is requested by the Japanese Pharmaceutical Affairs Law (J-PAL) in order to accumulate safety and efficacy data for reexamination. Reexamination period is defined by J-PAL. Eight years after approval of a new substance, results of PMS need to be submitted as a part of reexamination dossier to the Japanese regulatory authority, the Ministry of Health, Labour and Welfare (MHLW).
NCT02285361 ↗ GIOTRIF rPMS in Korean Patients With NSCLC Completed Boehringer Ingelheim 2014-10-31 To monitor the safety profile and efficacy of GIOTRIF┬« (afatinib dimaleate, q.d) in Korean patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Afatinib Dimaleate

Condition Name

Condition Name for Afatinib Dimaleate
Intervention Trials
Advanced Malignant Solid Neoplasm 3
Refractory Lymphoma 2
Recurrent Non-Small Cell Lung Carcinoma 2
Refractory Malignant Solid Neoplasm 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Afatinib Dimaleate
Intervention Trials
Carcinoma, Non-Small-Cell Lung 5
Lung Neoplasms 4
Neoplasms 3
Lymphoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Afatinib Dimaleate

Trials by Country

Trials by Country for Afatinib Dimaleate
Location Trials
United States 101
Japan 2
Korea, Republic of 1
China 1
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Afatinib Dimaleate
Location Trials
North Carolina 3
Illinois 3
Georgia 3
Pennsylvania 3
Indiana 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Afatinib Dimaleate

Clinical Trial Phase

Clinical Trial Phase for Afatinib Dimaleate
Clinical Trial Phase Trials
Phase 4 1
Phase 2/Phase 3 1
Phase 2 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Afatinib Dimaleate
Clinical Trial Phase Trials
Completed 3
Recruiting 3
Active, not recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Afatinib Dimaleate

Sponsor Name

Sponsor Name for Afatinib Dimaleate
Sponsor Trials
National Cancer Institute (NCI) 6
Boehringer Ingelheim 2
University of Chicago 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Afatinib Dimaleate
Sponsor Trials
NIH 6
Other 5
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Moodys
Express Scripts
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.